DLBCL-001
Diffuse Large B-Cell Lymphoma · CD19/CD20/BCL2 Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · HAEMATOLOGY← RESEARCH
Diffuse Large B-Cell Lymphoma
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
R-CHOP 6 Cycles PROVEN
60% long-term cure. CR 76%. 20yr standard.
Coiffier 2002 NEJM
Axicabtagene ZUMA-1 PROVEN
CD19 CAR-T r/r DLBCL. ORR 83%, CR 58%. 3yr OS 47%.
Neelapu 2017 NEJM
Tisagenlecleucel JULIET PROVEN
CD19 CAR-T r/r. CR 40%. Lentiviral 4-1BB.
Schuster 2019 NEJM
Polatuzumab Vedotin POLARIX PROVEN
CD79b ADC. PFS 76.7% vs 70.2% 2yr. FDA 2023 1st-line.
Tilly 2022 NEJM
Bispecifics Epcoritamab/Glofitamab OPEN
CD20/CD3. ORR 39-45% r/r. Outpatient alternative to CAR-T.
Hutchings 2021 NEJM glofitamab
Open Sorries — Click to Expand
S-1 SORRY-1 · CAR-T Only 40% Long-Term r/r
S-2 SORRY-2 · ICANS Neurotoxicity
S-3 SORRY-3 · Bridging Therapy Decisions
S-4 SORRY-4 · Primary Refractory DLBCL
S-5 SORRY-5 · Double/Triple-Hit Lymphoma
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
DLBCL-001 · R-CHOP 60% CURE · CAR-T r/r FRONTIER · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693